Revance Therapeutics, Inc. has launched DAXXIFY (DaxibotulinumtoxinA-lanm), a novel treatment for cervical dystonia, a painful condition. This marks Revance’s...

Reflow Spur™ Stent Clinical Trial Concludes Enrollment Reflow Medical, Inc. has successfully completed enrollment in the DEEPER REVEAL clinical...

Arcellx and Kite have partnered on the development of anitocabtagene autoleucel (anito-cel), a BCMA CAR T cell therapy for...

Merck’s Phase 3 KEYNOTE-B21 trial has shown that its anti-PD-1 therapy, KEYTRUDA, in combination with chemotherapy, did not improve...

Clinical trials have demonstrated the significant potential of SPT-300, an oral prodrug of the neurosteroid allopregnanolone. The Glyph™ platform...

As digital health technologies (DHTs) increasingly permeate the landscape of clinical trials, the European Medicines Agency (EMA) faces mounting...

ICON plc (NASDAQ: ICLR) has released its ICON Cares 2023 Report, outlining its achievements in environmental, social, and governance...

In this interview on integrating innovative digital technologies in central nervous system (CNS) trials, I engaged with Matthew Stork,...

Polo-like kinases (PLKs) are key players in cellular processes like cell cycle regulation and DNA damage response. Their dysregulation...

As a pioneer in oncological and hematological innovation, Massive Bio is showcasing its groundbreaking AI technology at the ASCO...